Advances and Controversies in the Biology and Therapy of Acute Leukemia and Myelodysplasia

Friday, March 25, 2011 – San Francisco, CA

7:00–7:40  Registration and Breakfast

7:45–7:50  Introduction
Jacob M. Rowe, Co-Chairman

Session 1: Basic Biology
Moderators: Marshall A. Lichtman, MD
Monica L. Guzman, PhD

7:50–8:05  Will new insights into the molecular pathogenesis of ALL translate into novel targeted therapies?
Charles G Mullighan, MD

8:05–8:15  Discussion

8:15–8:30  Does novel gene discovery in AML help us identify new therapeutic targets?
Ross L. Levine, MD

8:30–8:40  Discussion

8:40–8:55  What is the impact of proteomics on the diagnosis of leukemia?
Garry P. Nolan, Ph.D.

8:55–9:05  Discussion

9:05–9:25  Break

Session 2: Induction and Post-Remission Therapy
Moderators: Gary J. Schiller, MD
Dan Douer, MD

9:30–9:45  Should the presence of MRD in morphologic complete remission alter post-remission strategy?
Richard M. Stone, MD

9:45–9:55  Discussion

9:55–10:10  What is the optimal induction strategy for older adults with AML?
Elihu H. Estey, MD

10:10–10:20  Discussion

10:20–10:35  Does therapy-related AML have a poor prognosis, independent of the cytogenetic/molecular determinants?
Eric J. Feldman, MD

10:35–10:45  Discussion

10:45–11:00  Is a nadir bone marrow required and, if so, what to do with residual disease?
Selina Luger, MD
11:00–11:10 Discussion

11:10–11:25 What is the future of immunotherapy in AML?
Michael Caligiuri, MD

11:25–11:35 Discussion

11:35–12:35 Lunch

Session 3: Bone Marrow Transplantation

Moderators: Armand Keating, MD
Hillard M. Lazarus, MD

12:40–12:55 What is the optimal time to transplant a patient with MDS?
Frederick R. Appelbaum, MD

12:55–1:05 Discussion

1:05–1:20 Have we made progress in the treatment of GvHD?
TBD

1:20–1:30 Discussion

1:30–1:45 What is the optimal timing for transplanting a patient with relapsed/refractory acute leukemia?
Daniel J. Weisdorf, MD

1:45–1:55 Discussion

1:55–2:10 Has double cord replaced MUD as the preferred alternative donor?
John E. Wagner, MD

2:10–2:20 Discussion

2:20–2:40 Break

Session 4: Supportive Care and Perspective

Moderators: Beverly S. Mitchell, MD
Nancy Berliner, MD

2:45–3:00 What is the potential for thrombopoietic agents in acute leukemia?
David J. Kuter, MD, DPhil

3:00–3:10 Discussion

Keynote Address

3:10–3:20 Introduction of Robert C Gallo, MD
Vincent T. Devita, Jr., MD

3:20–3:50 Ernest Beutler Memorial Lecture
Research and discovery of the first human cancer virus, HTLV-1
Robert C Gallo, MD

3:50–3:55 Discussion

3:55–4:00 Concluding Remarks and Close
Martin S. Tallman, MD, Co-Chairman